Testosterone implants added to MIMS

Testosterone implants now listed in MIMS | SPL
Testosterone implants now listed in MIMS | SPL

Testosterone subcutaneous implants are now listed in MIMS.

The 100mg and 200mg implants are indicated for primary and secondary hypogonadism in males. Implants should be inserted into an area where there is relatively little movement or blood supply, such as the lower abdominal wall or buttock.

The recommended dose is 100-600mg. In most hypogonadal men a dose of 600mg maintains plasma testosterone levels within the normal physiological range for 4–5 months.

View Testosterone Implant drug record

Further information: MSD

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Drug shortages - live tracker

Drug shortages - live tracker

Check on the latest drug supply issues with MIMS' shortages...

Novel MS drug gains NICE approval

Novel MS drug gains NICE approval

New NICE guidance recommends ocrelizumab (Ocrevus)...

Emollients, Potential Skin Sensitisers as Ingredients

Emollients, Potential Skin Sensitisers as Ingredients

Potential sensitising agents in emollient preparations.

NICE recommends new triple therapy option for diabetes

NICE recommends new triple therapy option for diabetes

Ertugliflozin (Steglatro) can now be prescribed routinely...